Comparing Chemotherapy Treatments for Advanced Breast Cancer
Author Information
Author(s): S.C.A. Fraser, H.J. Dobbs, S.R. Ebbs, L.J. Fallowfield, T. Bates, M. Baum
Primary Institution: Kings College Hospital
Hypothesis
Does combination chemotherapy (CMF) provide better outcomes than low-dose epirubicin for patients with advanced breast cancer?
Conclusion
Combination chemotherapy (CMF) resulted in better response rates and similar survival compared to low-dose epirubicin, without significantly impairing quality of life overall.
Supporting Evidence
- Response rates were 58% for CMF and 29% for epirubicin.
- Median time to treatment failure was 24 weeks for CMF and 7 weeks for epirubicin.
- Survival was similar in both groups, with medians of 57 weeks for CMF and 55 weeks for epirubicin.
Takeaway
This study looked at two types of cancer treatments for women with advanced breast cancer. One treatment worked better at shrinking tumors, but both treatments had similar effects on how long patients lived.
Methodology
40 patients were randomized to receive either CMF or low-dose epirubicin, and their responses and quality of life were measured using various criteria and instruments.
Potential Biases
Potential biases in patient selection and response assessment due to the small sample size.
Limitations
The study had a small sample size and may not be generalizable to all patients with advanced breast cancer.
Participant Demographics
Median age of participants was 52 for epirubicin and 63 for CMF, with a mix of premenopausal and postmenopausal women.
Statistical Information
P-Value
0.02
Confidence Interval
95% c.i., -0.72, -0.23
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website